FOLD
Price
$11.65
Change
-$0.04 (-0.34%)
Updated
Sep 6 closing price
59 days until earnings call
MRNS
Price
$1.40
Change
+$0.01 (+0.72%)
Updated
Sep 6 closing price
59 days until earnings call
Ad is loading...

FOLD vs MRNS

Header iconFOLD vs MRNS Comparison
Open Charts FOLD vs MRNSBanner chart's image
Amicus Therapeutics
Price$11.65
Change-$0.04 (-0.34%)
Volume$1.69M
CapitalizationN/A
Marinus Pharmaceuticals
Price$1.40
Change+$0.01 (+0.72%)
Volume$271.58K
CapitalizationN/A
View a ticker or compare two or three
FOLD vs MRNS Comparison Chart
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRNS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
FOLD vs. MRNS commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a StrongBuy and MRNS is a Hold.

COMPARISON
Comparison
Sep 08, 2024
Stock price -- (FOLD: $11.69 vs. MRNS: $1.39)
Brand notoriety: FOLD and MRNS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 48% vs. MRNS: 29%
Market capitalization -- FOLD: $3.46B vs. MRNS: $77.12M
FOLD [@Biotechnology] is valued at $3.46B. MRNS’s [@Biotechnology] market capitalization is $77.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $584.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileMRNS’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • MRNS’s FA Score: 0 green, 5 red.
According to our system of comparison, MRNS is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 4 TA indicator(s) are bullish while MRNS’s TA Score has 6 bullish TA indicator(s).

  • FOLD’s TA Score: 4 bullish, 5 bearish.
  • MRNS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRNS is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +3.45% price change this week, while MRNS (@Biotechnology) price change was -0.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.71%. For the same industry, the average monthly price growth was +3.67%, and the average quarterly price growth was -3.87%.

Reported Earning Dates

FOLD is expected to report earnings on Nov 05, 2024.

MRNS is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Biotechnology (-2.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($3.46B) has a higher market cap than MRNS($77.1M). FOLD YTD gains are higher at: -17.618 vs. MRNS (-87.213). FOLD has higher annual earnings (EBITDA): -40.33M vs. MRNS (-131.2M). FOLD has more cash in the bank: 260M vs. MRNS (64.7M). MRNS has less debt than FOLD: MRNS (57.6M) vs FOLD (444M). FOLD has higher revenues than MRNS: FOLD (456M) vs MRNS (30.3M).
FOLDMRNSFOLD / MRNS
Capitalization3.46B77.1M4,481%
EBITDA-40.33M-131.2M31%
Gain YTD-17.618-87.21320%
P/E RatioN/AN/A-
Revenue456M30.3M1,505%
Total Cash260M64.7M402%
Total Debt444M57.6M771%
FUNDAMENTALS RATINGS
FOLD vs MRNS: Fundamental Ratings
FOLD
MRNS
OUTLOOK RATING
1..100
2618
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRNS's Valuation (50) in the Pharmaceuticals Other industry is in the same range as FOLD (82) in the Biotechnology industry. This means that MRNS’s stock grew similarly to FOLD’s over the last 12 months.

FOLD's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that FOLD’s stock grew similarly to MRNS’s over the last 12 months.

FOLD's SMR Rating (98) in the Biotechnology industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that FOLD’s stock grew similarly to MRNS’s over the last 12 months.

FOLD's Price Growth Rating (45) in the Biotechnology industry is in the same range as MRNS (64) in the Pharmaceuticals Other industry. This means that FOLD’s stock grew similarly to MRNS’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MRNS (100) in the Pharmaceuticals Other industry. This means that FOLD’s stock grew similarly to MRNS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDMRNS
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 5 days ago
75%
Bullish Trend 18 days ago
81%
Declines
ODDS (%)
Bearish Trend 11 days ago
74%
Bearish Trend 3 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
75%
View a ticker or compare two or three
Ad is loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRNS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TCMSX45.09N/A
N/A
Voya Small Cap Growth I
CNRWX27.05-0.09
-0.33%
City National Rochdale US Cor Eq N
SPSDX19.41-0.09
-0.46%
Sterling Capital Behav Sm Cp Val Eq C
LMVTX95.89-0.59
-0.61%
ClearBridge Value C
CWMFX61.75-0.46
-0.74%
American Funds Washington Mutual 529F1

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with NTLA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+1.48%
NTLA - FOLD
51%
Loosely correlated
-1.55%
DNLI - FOLD
49%
Loosely correlated
+0.42%
FULC - FOLD
49%
Loosely correlated
+4.73%
BBIO - FOLD
47%
Loosely correlated
+2.09%
VCEL - FOLD
46%
Loosely correlated
-1.90%
More

MRNS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNS has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNS
1D Price
Change %
MRNS100%
-2.11%
AXON - MRNS
40%
Loosely correlated
-0.14%
VIRX - MRNS
39%
Loosely correlated
+1.93%
FOLD - MRNS
36%
Loosely correlated
+1.48%
AMRN - MRNS
35%
Loosely correlated
-0.25%
BHVN - MRNS
33%
Loosely correlated
-2.46%
More